Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 4,292 shares at $40.00 ($172K) on 2025-06-10, disclosed to the SEC on 2025-06-11.
Scheduled sale ($172k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |